Louis Plamondon
About Louis Plamondon
Louis Plamondon is the EVP and Head of CMC at LifeMine Therapeutics, with a Ph.D. in Organic Chemistry from the Université de Montréal and postdoctoral experience at Harvard University.
Louis Plamondon Education
Louis Plamondon earned his Ph.D. in Organic Chemistry from the Université de Montréal. His doctoral research was conducted under the supervision of James D. Wuest. Following his Ph.D., Plamondon completed a postdoctoral fellowship at Harvard University, where he worked under the guidance of Stuart L. Schreiber.
Louis Plamondon Professional Background
Louis Plamondon is currently the Executive Vice President (EVP) and Head of Chemistry, Manufacturing, and Controls (CMC) at LifeMine Therapeutics. Before joining LifeMine Therapeutics, he served as the Senior Vice President (SVP) and Head of CMC at Constellation Pharmaceuticals, a company now part of MorphoSys.
Louis Plamondon Achievements
Louis Plamondon has co-invented notable pharmaceuticals. He was a co-inventor and leader for Velcade® (bortezomib), the first proteasome inhibitor approved for treating multiple myeloma. Additionally, he co-invented Xerava® (Eravacycline), the first fully synthetic fluorocycline approved for complicated intra-abdominal infections (cIAI).